CN1200723C - White peony and licorice extract and its prepn process - Google Patents
White peony and licorice extract and its prepn process Download PDFInfo
- Publication number
- CN1200723C CN1200723C CN 02156681 CN02156681A CN1200723C CN 1200723 C CN1200723 C CN 1200723C CN 02156681 CN02156681 CN 02156681 CN 02156681 A CN02156681 A CN 02156681A CN 1200723 C CN1200723 C CN 1200723C
- Authority
- CN
- China
- Prior art keywords
- extract
- radix glycyrrhizae
- paeoniae alba
- radix paeoniae
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000236658 Paeonia lactiflora Species 0.000 title abstract description 9
- 235000008598 Paeonia lactiflora Nutrition 0.000 title abstract description 9
- 238000000034 method Methods 0.000 title abstract description 6
- 229940069445 licorice extract Drugs 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 67
- 239000002253 acid Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 12
- 229930182478 glucoside Natural products 0.000 claims abstract description 11
- 150000008131 glucosides Chemical class 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000010828 elution Methods 0.000 claims description 19
- 229920005989 resin Polymers 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 13
- 229930003944 flavone Natural products 0.000 claims description 12
- 150000002213 flavones Chemical class 0.000 claims description 12
- 235000011949 flavones Nutrition 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- 229930182470 glycoside Natural products 0.000 claims description 10
- 150000002338 glycosides Chemical class 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 20
- 230000036407 pain Effects 0.000 abstract description 18
- 241000202807 Glycyrrhiza Species 0.000 abstract description 14
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract description 14
- 230000002496 gastric effect Effects 0.000 abstract description 14
- 229940010454 licorice Drugs 0.000 abstract description 14
- 208000005392 Spasm Diseases 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 7
- 230000001154 acute effect Effects 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 206010062575 Muscle contracture Diseases 0.000 abstract description 5
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 208000006111 contracture Diseases 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 206010019799 Hepatitis viral Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 229930003935 flavonoid Natural products 0.000 abstract description 2
- 150000002215 flavonoids Chemical class 0.000 abstract description 2
- 235000017173 flavonoids Nutrition 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract 1
- 238000005562 fading Methods 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000002435 tendon Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 235000009508 confectionery Nutrition 0.000 description 27
- 241000736199 Paeonia Species 0.000 description 26
- 235000006484 Paeonia officinalis Nutrition 0.000 description 26
- 230000000694 effects Effects 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 14
- 210000002460 smooth muscle Anatomy 0.000 description 14
- 230000008602 contraction Effects 0.000 description 12
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 10
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 10
- 210000004291 uterus Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 8
- 230000008485 antagonism Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000007107 Stomach Ulcer Diseases 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010018691 Granuloma Diseases 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000036592 analgesia Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 201000005917 gastric ulcer Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- -1 pinane monoterpene Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- ILKBHIBYKSHTKQ-UHFFFAOYSA-N Diisopropylamine dichloroacetate Chemical compound OC(=O)C(Cl)Cl.CC(C)NC(C)C ILKBHIBYKSHTKQ-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010052541 Gastric volvulus Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000008886 Stomach Volvulus Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940084113 diisopropylamine dichloroacetate Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229930006728 pinane Natural products 0.000 description 1
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane of uncertain configuration Natural products CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to white peony and licorice extracts and a preparing method thereof. The weight of the following proportion is of 1 portion of white peony to 1 portion of licorice of the present invention to 3 portions of the white penoy to 1 portion of the licorice, and particular preparing methods are shown in a specification. The present invention has the advantages that the extracts contain three active part groups of total glucosides of white penoy, licorice total flavonoids and licorice triterpenic acid. The total contents are bigger than 50%, therapeutic effects are good, and 1 to 3 combination of the three positions, or the single or combination use all has spasm relieving and pain stopping functions at different degrees. The single type combination use of the three types of extracts has obvious pain reliving functions. The white peony and licorice extracts are made into powder which can be made into oral preparations or injections. Products of the present invention have sour-sweet herbs nourishing yin and emergency pain reliving functions, and are mainly used for treating deficiency of yin-blood, non-free blood circulation, hand and foot spasm shown in symptoms, tendon and vessel contracture, gastric cavity and ventral pain, etc. The present invention is mainly used for relieving spasm and pain for nerve, muscle and splanchnic acute chronic spasm pain, nourishing blood, protecting the liver, removing toxin, alleviating pain, lowering enzymes, fading yellow, treating acute chronic virus hepatitis, etc.
Description
Technical field
The present invention relates to the extraction of Chinese herbal medicine, the specifically Radix Paeoniae Alba and Radix Glycyrrhizae extract, and preparation method thereof.
Background technology
The present invention is so that classical ancient prescription---peony and licorice decoction is the research and development of basis side in the Zhang Zhongjing " Treatise on Febrile Diseases is distinguished sun abnormal pulse card and controls ".Shaogan soup prescription is made up of the Radix Paeoniae Alba, Radix Glycyrrhizae each four liang (each 12g), the long-term clinical practice proof to blood deficiency Tianjin hinder, smooth muscle due to the disharmony between QI and blood, striate acute and chronic pain be effective, prescription is reasonable, curative effect is sure, toxic and side effects is little.Chinese scholars was done a lot of researchs to the clinical and pharmacology of shaogan soup, and the chemical constituent of Radix Paeoniae and Radix Glycyrrhizae has also been made big quantity research.
The report that lot of documents and case are arranged clinically, summary get up effective to the anxious pain of the contraction of the spasm pain of multiple nerve, musculature, visceral smooth muscle.No matter be central, tip, sedation is all arranged, can alleviate contraction anxious, prevent pain.
Chemically: Radix Paeoniae mainly comprises two kinds of the Radix Paeoniae Alba and Radix Paeoniae Rubra, and the Radix Paeoniae effective ingredient is the Radix Paeoniae glycoside.It is a class pinane monoterpene.The main effective ingredient of Radix Glycyrrhizae is triterpene acids (glycyrrhizic acid, enoxolone etc.) and flavonoid (FM--100).
On the pharmacology: myokinesis has inhibitory action, the inhibition gastric secretion is arranged to gastrointestinal smooth.Analgesia, calmness, antiinflammation are arranged.To nerve--the muscle conduction has blocking effect.
Shaogan soup has been developed as three kind new medicines (Chinese medicine)-strong diisopropylamine dichloroacetate granule, treatment acute and chronic hepatitis with water extraction.But because the Radix Paeoniae Alba, Radix Glycyrrhizae use water extraction, it is lower that extract contains Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae total flavones, three effective part group content of Radix Glycyrrhizae triterpenic acid, how to improve the content and the curative effect of effective part group, and this is one of urgency problem to be solved at present.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art part, and provide easy to prepare, eutherapeutic Radix Paeoniae Radix Glycyrrhizae extract, and preparation method thereof.
The object of the invention can reach by following measure:
Radix Paeoniae Alba Radix Glycyrrhizae extract is by the Radix Paeoniae Alba: the Radix Glycyrrhizae weight ratio is 1: 1-3: 1, and Radix Paeoniae Alba Radix Glycyrrhizae is mixed or use the 40-80% alcohol reflux respectively, extract three times, merge extractive liquid,, be concentrated into when not having alcohol adding distil water to 3 times volume, filtration or centrifugal, filtrate is mixed or is gone up macroporous resin column respectively, elder generation's water is eluted to no reducing sugar reaction, and reuse 20-95% ethanol elution merges ethanol elution to there not being the glycosides reaction, be evaporated to dried, Radix Paeoniae Alba Radix Glycyrrhizae extract.
The preparation method of Radix Paeoniae Alba Radix Glycyrrhizae extract is that the Radix Paeoniae Alba or Radix Glycyrrhizae mix or extraction respectively, uses the 40-80% alcohol reflux, extract three times (being preferably 60-70%), merge extractive liquid, is concentrated into when not having alcohol adding distil water to 3 times volume, filtration or centrifugal, filtrate is mixed or is gone up macroporous resin column respectively, is washed with water to no reducing sugar reaction earlier, and reuse 20-95% ethanol elution is to there not being glycosides reaction (being preferably 50-70%), ethanol elution is evaporated to dried, gets faint yellow or pale brown toner end.
Extract dry powder and suitable pharmaceutic adjuvant are made oral formulations or injection together, can be several formulations such as tablet, capsule, granule, pill, powder, lozenge, oral liquid, injection, transfusion.
Radix Paeoniae Alba Radix Glycyrrhizae extract contains three effective part group-Radix Paeoniae Alba total glucosidess, Radix Glycyrrhizae total flavones and Radix Glycyrrhizae triterpenic acid, and the total content of three effective part groups is greater than 50%, and these three effective part groups can be individual independent or several for 1-3, combines with different ratios.
Radix Paeoniae Alba Radix Glycyrrhizae is extract obtained Radix Paeoniae Alba total glucosides after extracting, Radix Glycyrrhizae total flavones, Radix Glycyrrhizae triterpenic acid, i.e. several groups of best of breeds of three effective part groups such as table 1
Radix Paeoniae Alba total glucosides mg dry powder/kg Radix Glycyrrhizae total flavones mg dry powder Radix Glycyrrhizae triterpenic acid mg dry powder
(the g crude drug/kg)/kg/kg
(the g crude drug/and kg) (the g crude drug/kg)
160(6.4) 400(8.4) 150(3.8)
160(6.4) 200(4.2) 300(7.6)
320(12.8) 200(4.2) 300(7.6)
The extracting solution of the Radix Paeoniae Alba and Radix Glycyrrhizae can be crossed macroporous adsorptive resins respectively and handle, and also may be mixed together macroporous adsorptive resins.Macroporous adsorbent resin can be used the macroporous adsorbent resins styrene skeleton or other types, as: D-101, DM-301, ADS-series, NKA-series, AB-8, X-5, Amberlite XAD-series, Diaion Hp-series etc.With the effective part group (Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae total acid and Radix Glycyrrhizae total flavones) of absorption with macroporous adsorbent resin, reuse Diluted Alcohol eluting from the macroporous adsorbent resin, concentration of ethanol is better with 50%-70%.Eluent is through concentrating under reduced pressure and be spray dried to extract dry powder.
The present invention has following advantage compared to existing technology: behind ethanol extraction Radix Paeoniae Alba Radix Glycyrrhizae, three effective part group Radix Paeoniae Alba total glucosidess of gained, Radix Glycyrrhizae total flavones, Radix Glycyrrhizae triterpenic acid extractive content height, good effect, any 1-3 in three positions combination, separately or compatibility use and all have tangible relieving spasm to stop pain effect, its analgesia degree and medium analgesic indomethacin 4mg/kg are quite or better.
The specific embodiment
Enumerate four embodiment below, the present invention is further specified.
Embodiment one:
Get 2kg Radix Paeoniae Alba crude drug granule,, extract 2 times with 16L 70% alcohol reflux, each 1 hour.Filter merge extractive liquid.Be concentrated into and do not have alcohol flavor, adding distil water to 3 times volume.Centrifugal, macroporous resin column on the supernatant is eluted to no reducing sugar reaction with distilled water earlier, and reuse 50% ethanol elution is to there not being the glycosides reaction.Merge ethanol elution, be evaporated to driedly, obtain pale yellow powder 80g (containing Radix Paeoniae Alba total glucosides more than 50%).
Get the 1kg licorice piece,, extract centrifugal filtration, merge extractive liquid, 3 times with 10L 60% alcohol reflux, each 1 hour.Be concentrated into and do not have alcohol flavor, adding distil water to 3 times volume.Filter.Macroporous resin column on the filtrate is eluted to no reducing sugar reaction with distilled water earlier, and reuse 70% ethanol elution is to there not being the glycosides reaction.Merge ethanol elution, be evaporated to driedly, obtain pale brown toner end 155g (containing Radix Glycyrrhizae triterpenic acid and Radix Glycyrrhizae total flavones more than 50%).
Embodiment two:
Get 2kg Radix Paeoniae Alba crude drug granule,, extract 2 times with 16L 40% alcohol reflux, each 1 hour.Filter merge extractive liquid.Be concentrated into and do not have alcohol flavor, adding distil water to 3 times volume.Centrifugal, macroporous resin column on the supernatant is eluted to no reducing sugar reaction with distilled water earlier, and reuse 20% ethanol elution is to there not being the glycosides reaction.Merge ethanol elution, be evaporated to driedly, obtain pale yellow powder 75g (containing Radix Paeoniae Alba total glucosides more than 50%).
Get the 1kg licorice piece,, extracts filtration, merge extractive liquid, 3 times with 10L 60% alcohol reflux, each 1 hour.Being concentrated into does not have the alcohol flavor, adds water to 2 times of volumes, adds hydrochloric acid and transfers pH to 2, is placed to precipitation fully, filters.Filtering residue washes with water, extracts with Diluted Alcohol, and the Diluted Alcohol extracting solution is concentrated into dried pale brown toner end 98g (containing the Radix Glycyrrhizae triterpenic acid more than 50%).
Filtrate is used adjusting PH with base 7, last macroporous resin column, and first water is eluted to no reducing sugar reaction, and reuse 95% ethanol elution is to there being the glycosides reaction.Merge ethanol elution, be evaporated to driedly, obtain pale brown toner end 55g (containing Radix Glycyrrhizae total flavones more than 50%).
Embodiment three:
Get Radix Paeoniae Alba 2kg and Radix Glycyrrhizae 1kg medical material granule or decoction pieces, mix with 30L 60% alcohol reflux 3 times, merge extractive liquid,, being concentrated into does not have the alcohol flavor, and adding distil water to 3 times volume filters.Macroporous resin column on the filtrate is eluted to no reducing sugar reaction with distilled water, reuse 70% ethanol elution earlier.Merge ethanol elution, be evaporated to and do or spray drying, obtain pale brown toner end 246g (containing Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae triterpenic acid and Radix Glycyrrhizae total flavones more than 50%).
Embodiment four:
Get Radix Paeoniae Alba 2kg and Radix Glycyrrhizae 1kg medical material granule or decoction pieces, mix with 30L 80% alcohol reflux 3 times, merge extractive liquid,, being concentrated into does not have the alcohol flavor, and adding distil water to 3 times volume filters.Macroporous resin column on the filtrate is eluted to no reducing sugar reaction with distilled water, reuse 70% ethanol elution earlier.Merge ethanol elution, be evaporated to and do or spray drying, obtain pale brown toner end 232g (containing Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae triterpenic acid and Radix Glycyrrhizae total flavones more than 50%).
Enumerate five application examples below:
Application example 1
Get the extract of 2kg white Peony Root and 1kg licorice medicinal materials, pulverize and cross 100 mesh sieves, add appropriate amount of starch to 300g, mix homogeneously.With 80% ethanol is binding agent, is rolled onto 10-20 purpose micropill in coating pan.Packing, every 1.2g is one bag.
Every day 3 times, each 1 bag.
Application example 2
Get the extract of 2kg white Peony Root and 1kg licorice medicinal materials, pulverizing is also crossed 100 mesh sieves, adds an amount of Icing Sugar to 300g, mix homogeneously.With 90% ethanol is binding agent, crosses 40 mesh sieves and makes granule, and packing is carried out in 60 ℃ of oven dry behind the granulate, and every 1.2g is one bag.
Every day 3 times, each 1 bag.
Application example 3
Get the extract of 2kg white Peony Root and 1kg licorice medicinal materials, pulverize and cross 100 mesh sieves, add appropriate amount of starch to 300g, mix homogeneously.Adorn capsule No. 0, make 1000 seed lac wafers.
Every day 3 times.Each 4.
Or by the method for Application Example 2, cross 60 mesh sieves and granulate, capsule is adorned in 60 ℃ of oven dry No. 0 behind the granulate, make 1500.
Every day 3 times.Each 6.
Application example 4
Get the extract of 2kg white Peony Root and 1kg licorice medicinal materials, pulverize the back and cross 100 mesh sieves, mixing, add microcrystalline Cellulose 20g, transfer to 300g with amylum pregelatinisatum, add 0.5% magnesium stearate again, powder directly is pressed into 1000 behind the mix homogeneously, makes tablet.
Every day 3 times, each 4.
Application example 5
Get the extract of 2kg white Peony Root and 1kg licorice medicinal materials, add the about 8000ml of injection water, transfer to pH 7.3-7.5 with 5%NaOH solution.Add the injection water to 10000ml, filter with No. 3 sintered filter funnels.Embedding in ampoule, every 2ml, sterilization is made injection.
Each 1, intramuscular injection or intravenous drip are used.
The present invention is to three effective part groups in Radix Paeoniae and the Radix Glycyrrhizae: Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae total flavones, three extracts of Radix Glycyrrhizae triterpenic acid cause pain model with the mice chemistry, the side of tearing open and prescription screening, promptly adopt methods such as orthogonal experiment factor analysis to carry out the analgesia effective dosage ranges, optimal dose and best of breed, Study of Interaction.
The sweet extract pharmacological testing of Chinese herbaceous peony proves: spasmolytic, analgesia, antiulcer, antiinflammatory, protect the liver etc. all had tangible effect.
One. spasmolytic, analgesic activity:
1. the influence that the mice acetic acid twisting is reacted:
The result shows that high, middle dosage group has significant analgesia role, with matched group significant difference (P＜0.01-0.001) is arranged relatively.
The analgesic activity of Dichlorodiphenyl Acetate writhing response (x ± s)
Group dosage number of animals is turned round body and the moving body number of times of turning round occurred
(mg/k) (only) thing number (only)
Blank group-10 10 29.60 ± 10.43
Indomethacin 5 10 4 0.6 ± 0.97
* *
High dose 800 10 9 12.8 ± 7.86
*
Middle dosage 400 10 10 13.1 ± 7.43
*
Low dosage 200 10 10 16.0 ± 12.51
Annotate: compare with the blank group
*P＜0.01,
* *P＜0.001.
2. to the violent influence of shrinking in uterus due to the oxytocin
The result shows that the sweet extract high dose group of Chinese herbaceous peony causes the contraction of rat uterus spasm to oxytocin and has tangible spasmolysis.
The sweet extract of Chinese herbaceous peony causes the influence (x ± s) of the rat uterus pain sensation to oxytocin
Group dosage number of animals is turned round the body number of times and is turned round the body incidence rate
(mg/ (only) (%)
kg) 30min 60min 30min 60min
Blank group-5 2.80 ± 1.92 4.40 ± 1.52 80 100
FUTONGNING 5 0.4 ± 0.55* 1.00 ± 1.00** 40 60
High dose 400 5 0.80 ± 0.84 2.00 ± 1.00* 60 100
Middle dosage 200 5 2.80 ± 1.92 4.00 ± 1.22 80 100
Low dosage 100 5 3.80 ± 1.48 5.20 ± 1.10 100 100
Annotate: compare with the blank group
*P＜0.05,
*P＜0.01.
Two. to the influence of gastrointestinal motility function
1. to the influence of full gastric motor function
Use the male mice administration by gavage, measure relative gastric pigment residual rate.The result shows height, and middle dosage group can make gastric emptying, gastric peristalsis slow down, and with matched group significant difference (P＜0.05) is arranged relatively.
The sweet extract of Chinese herbaceous peony is to the influence of mice gastric emptying (x ± s)
The relative gastric pigment of group dosage number of animals residual rate
(mg/kg) (only)
Blank group-10 100.00 ± 39.79
Atropine 20 10 158.94 ± 34.31*
High dose 400 10 144.82 ± 29.32*
Middle dosage 200 10 147.03 ± 39.96*
Low dosage 100 10 105.13 ± 43.23
Annotate: compare with the blank group
*P＜0.05.
2. the influence that intestinal propulsion is moved:
With mouse assay prepared Chinese ink at the enteral advance distance.The result shows each dosage group of the sweet extract of Chinese herbaceous peony intestinal propulsion speed that obviously slows down, and the propelling rate reduces, but does not influence the intestinal volume.With matched group significant difference (P＜0.05) is arranged relatively.
Influence (x ± s n=10) to the mouse small intestine wriggling
Group dosage small intestinal length overall prepared Chinese ink advances apart from prepared Chinese ink propelling rate intestinal volume
(mg/kg) degree (cm) (%) changes from (cm)
Blank group-47.3 ± 5.8 39.8 ± 7.7 84.1 is constant
WEISU KELI 1,200 45.6 ± 4.1 45.2 ± 4.2 99.1 enlarges slightly
High dose 800 47.2 ± 3.2 31.2 ± 5.6* 66.1 is constant
It is middle that dosage 400 47.1 ± 2.7 29.9 ± 12.4* 63.2 is constant
Low dosage 200 46.4 ± 2.4 30.1 ± 5.8** 64.6 is constant
Annotate: compare * P＜0.05 with the blank group, * * P＜0.01.
Three. to the influence of inflammatory model:
1. to the influence of the swollen chronic inflammatory disease of rat granuloma:
Male rat granuloma induced by implantation of cotton pellets hypertrophy method measurement result shows to have the swollen outgrowth effect (P＜0.05) of obvious inhibition rat granuloma with blank group comparison high dose group.
To the exercising result of the swollen chronic inflammation model of rat granuloma (x ± s)
Group dosage number of animals (only) granuloma relative weight
(mg/kg) (mg/100g Mus body weight)
Blank group-10 52.36 ± 6.11
Indomethacin 8 10 40.17 ± 4.04***
High dose 800 10 45.28 ± 6.12*
Middle dosage 400 10 48.82 ± 5.03
Low dosage 200 10 51.33 ± 3.92
Annotate: compare * P＜0.05 with the blank group, * * * P＜0.001.
2. to the influence of acute inflammation mice ear:
The mice ear result of the test shows, compares with the blank group, and high, medium and low dosage group has the obvious suppression effect to mice ear, dose-effect relationship clear and definite (P＜0.05).
The inhibitory action result of the inductive mice ear of xylol (x ± s)
Dosage
Group number of animals (only) ear swelling percentage rate (%)
(mg/kg)
Blank group-10 103.26 ± 24.35
Indomethacin group 10 10 58.47 ± 19.14***
High dose group 800 10 68.11 ± 24.10***
Middle dosage group 400 10 74.56 ± 25.44**
Low dose group 200 10 81.13 ± 21.10*
Annotate: compare * P＜0.05 with the blank group, * * P＜0.01, * * * P＜0.001
Four. to the influence of exsomatize intestinal smooth muscle and uterine smooth muscle
1. to the influence of the intestinal smooth muscle that exsomatizes
Rat preduodenal and jejunum show the antagonism experimental result that Ach (acetylcholine) causes the intestinal smooth muscle spasm, three dosage groups of the sweet extract of Chinese herbaceous peony, with the increase of dosage, its antagonism Ach is obvious more to the tetanic contraction of intestinal smooth muscle, and obviously reduce shrinkage amplitude, reduce contraction frequency; Three dosage groups have the obvious suppression effect to intestine in vitro, and are obvious more to the reduction of intestinal shrinkage amplitude with the increase of drug dose, with the solvent group significant difference (P＜0.01) arranged relatively.
The sweet extract of Chinese herbaceous peony is to the influence of isolated rat intestinal shrink tension
Group dosage shrink tension (g) (x ± s)
Solvent 0.05ml 0.33+0.19
0.1ml 0.31+0.19
0.2ml 0.34+0.19
The sweet extract 0.05ml of Chinese herbaceous peony * 30% 0.14+0.11#
0.1ml×30％ 0.18+0.13#
0.2ml×30％ 0.11+0.10##
Ach 0.1ml×3×10E-3mol/l 1.91+0.40
Sweet extract+Ach 30% * the 0.05ml+0.1ml of Chinese herbaceous peony * 3 * 10 0.99+0.37**
E-3mol/l
30％×0.1ml 1.11+0.19**
+0.1ml×3×10E-3mol/l
30％×0.2ml 0.96+0.44**
+0.1ml×3×10E-3mol/l
The sweet extract 0.1ml of Ach+ Chinese herbaceous peony * 3 * 10E-1.22+0.76*
3mol/l+30％×0.05ml
0.1ml×3×10E- 1.28+1.20
3mol/l+30％×0.1ml
0.1ml×3×10E- 1.30+0.48**
3mol/1+30％×0.2ml
Annotate: compare * P＜0.05, * * P＜0.01 with the Ach group.
Compare #P＜0.05, ##P＜0.01 with respective concentration solvent group.
2. to the influence of isolated rat uterine activity
The experimental result that influences to normal isolated uterine smooth muscle shows: the rat uterus of solvent matched group has tangible autorhythmicity to shrink in Lai Shi liquid.The sweet extract 0.025ml of Chinese herbaceous peony organizes, and can slightly reduce the amplitude and the frequency of uterine smooth muscle shrinkage curve; The sweet extract 0.05ml group of Chinese herbaceous peony can obviously reduce the amplitude and the frequency of uterine contraction curve; The sweet extract 0.1ml group of Chinese herbaceous peony can obviously suppress the uterus rhythmicity and shrink, and makes contraction wave flatten smooth or disappearance, and the effect of relaxing smooth muscle is arranged.
The sweet extract of Chinese herbaceous peony shows the antagonism experiment of pituitrin: the pituitrin positive controls, and can make uterine smooth muscle occur tetanic contraction rapidly, occur frequency of uterine contraction then and speed, wave amplitude increases.The sweet extract 0.025ml group of Chinese herbaceous peony has and weakens the trend that pituitrin shrinks uterine smooth muscle; The sweet extract 0.05ml group of Chinese herbaceous peony can shorten the persistent period that pituitrin shrinks the uterus strongly, but part antagonism pituitrin is to the effect in uterus.The sweet extract 0.1ml of Chinese herbaceous peony group, the obviously effect in the excited uterus of antagonism pituitrin makes the amplitude of the tetanic contraction in uterus that pituitrin causes diminish frequency deceleration, so that contraction wave disappearance rapidly.
To the influence of isolated mouse uterine contraction tension force and contraction frequency (x ± s)
Group dosage shrink tension changing value contraction frequency (inferior/
Divide)
Solvent 0.05ml 1.23 ± 0.03 0.79 ± 0.23
The sweet extract 0.025ml of Chinese herbaceous peony * 30% 0.59 ± 0.90* 0.62 ± 0.19
0.05ml?×30％ 0.17±1.07** 0.86±0.59
0.1ml?×30％ 0.19±0.71*** 0.00±0.00***
Pituitrin 0.1u * 3 * 10E-3mol/l 3.19 ± 0.76 2.90 ± 2.04***
Pituitrin+0.1u+30% * 0.025ml 0.74 ± 0.94### 1.35 ± 0.32#
The sweet extract 0.1u+30% * 0.05ml of Chinese herbaceous peony 1.01 ± 1.19### 1.28 ± 0.50
0.1u+30％×0.1ml 2.10±1.23# 0.80±0.50##
Annotate: compare #P＜0.05 with the pituitrin group, ##P＜0.01, ###P＜0.001.
Compare * P＜0.05 with the solvent group, * * P＜0.01, * * * P＜0.001.
Five. to the influence of gastric ulcer model:
1. water seaoning is induced the influence of rat gastric ulcer model
Experimental result shows that the stress ulcer that each dosage group causes water seaoning has tangible antagonism, and the ulcer incidence rate is reduced with matched group relatively significant difference (p＜0.05-0.001).
To the influence of the inductive rat gastric ulcer model of water seaoning (x ± s)
Group dosage number of animals gastric ulcer index ulcer inhibition rate
(mg/kg) (only) (%)
Blank group-10 11.30 ± 5.10-
WEISU KELI 8,000 10 4.20 ± 4.39** 62.83
High dose 400 10 6.30 ± 5.36* 44.25
Middle dosage 200 10 6.10 ± 5.16* 46.02
Low dosage 100 10 4.00 ± 3.20** 64.60
Annotate: compare * P＜0.05 with the blank group, * * P＜0.01.
2. anti-ethanol causes the gastric mucosa injury test
Ethanol causes the gastric mucosa injury experimental result and shows that compare with the blank group, high, middle dosage group all has obvious inhibitory action to gastric mucosa injury, with matched group significant difference (P＜001) is arranged relatively; Low dose group also has certain effect.
The sweet extract of Chinese herbaceous peony causes the influence of gastric mucosa injury and suppression ratio to ethanol
The size of animal dosage ulcer index (ulcer inhibition rate of x ± S)
Group number
(only) be (%) (mg/k)
Blank 10-103.3 ± 40.9
WEISU KELI 10 8,000 46.3 ± 18.1** 55.2
The sweet extract 10 100 45.2 of Chinese herbaceous peony ± 19.8 56.2
The sweet extract 10 200 16.3 ± 8.8** 84.2 of Chinese herbaceous peony
The sweet extract 10 400 15.7 ± 10.7** 84.8 of Chinese herbaceous peony
Annotate: compare * * P＜0.01 with the blank group
3. aspirin is induced the influence of rat acute gastritis model
The result shows, each dosage group has aspirin caused acute gastritis and significantly alleviates effect, and the ulcer incidence rate is reduced, and with matched group significant difference (P＜0.05) is arranged relatively.
The influence of the inductive rat gastritis of table 14. couple Asprin model (x ± s)
Group dosage (mg/kg) number of animals (only) gastric ulcer index
Blank group-5 5.80 ± 4.44
WEISU KELI 8,000 5 2.50 ± 1.10*
High dose 400 5 2.10 ± 1.91*
Middle dosage 200 5 1.80 ± 1.68*
Low dosage 100 5 2.30 ± 1.21*
Annotate: compare * P＜0.05 with the blank group
Above-mentioned pharmacological testing shows that Radix Paeoniae Radix Glycyrrhizae effective site group extract shows: the pain that mice acetic acid is caused has significant analgesia role, obviously reduces and turns round the body frequency; The rat uterus angor that oxytocin is caused has tangible spasmolysis; Has the intestinal smooth muscle contraction function under the obvious inhibition normal tension; The obvious contractile function of isolated rat intestinal smooth muscle due to the antagonism acetylcholine; Also have obvious inhibition uterine smooth muscle contraction movement, the also obviously excited uterine smooth muscle effect of antagonism pituitrin, and all have obvious dose-effect relationship.The sweet extract of Chinese herbaceous peony has the progradation of obvious suppression gastrointestinal, and obviously slow down full gastric peristalsis and small intestinal peristalsis make gastrointestinal advance the time obviously to slow down, and gastrointestinal emptying is obviously reduced.Xylol causes ear swelling and rat chronic granuloma induced by implantation of cotton pellets inflammatory model is had the obvious suppression effect.The sweet extract gastric infusion of Chinese herbaceous peony has the obvious suppression effect to multiple ulcer model, can obviously reduce the generation that water seaoning is induced rat gastric ulcer; Ethanol is caused the gastric mucosa injury test all have significant inhibitory effect; The inductive rat gastritis of Asprin model had the obvious suppression effect.
In addition, the sweet extract of Chinese herbaceous peony can obviously reduce mice serum ALT and the AST that D-galactose and carbon tetrachloride cause and increase, and obviously alleviates hepatocellular degeneration and necrosis, and the mouse experiment liver damage is had significant protective effect.
Therefore, effective site group extract of the present invention and preparation thereof have the function of sour and sweet drugs can transforme into YIN, relieving spasm to stop pain, cure mainly deficiency of YIN-blood, hematogenous blockage, and disease is seen contracture of the limbs, muscle arteries and veins contracture, epigastric pain, stomach network contracture etc.Be used for the relieving spasm to stop pain of the anxious pain of acute and chronic contraction of nerve, muscle and internal organs.For example, musculature disease: sural spasm, facial spasm, chorea minor, lower limb contracture pain; Nervous system disease: trigeminal neuralgia, sciatica, costalgia of chest and intercostal neuralgia, neurosis headache; Digestive system disease gastric abscess, gastric and duodenal ulcers, women's menstrual pain, gastric volvulus, bellyworm disease, stomachache and ascaris intestinal obstruction, acute edematous pancreatitis.
Effective site group extract of the present invention and preparation thereof nourish blood in addition hepatoprotective, the detoxifcation pain relieving, the function that enzyme takes off Huang is fallen, can treat acute and chronic viral hepatitis etc.
Claims (5)
1, Radix Paeoniae Alba Radix Glycyrrhizae extract is characterized in that by the Radix Paeoniae Alba: the Radix Glycyrrhizae weight ratio is 1: 1-3: 1, and Radix Paeoniae Alba Radix Glycyrrhizae mixed or use the 40-80% alcohol reflux respectively, extract three times, merge extractive liquid, is concentrated into when not having alcohol, adding distil water to 3 times volume, filtration or centrifugal, filtrate is mixed or is gone up macroporous resin column respectively, and first water is eluted to no reducing sugar reaction, reuse 20-95% ethanol elution is to there not being the glycosides reaction, merge ethanol elution, be evaporated to dried, Radix Paeoniae Alba Radix Glycyrrhizae extract.
2, Radix Paeoniae Alba Radix Glycyrrhizae extract according to claim 1 is characterized in that: the total content of Radix Paeoniae Alba total glucosides, Radix Glycyrrhizae total flavones and three effective part groups of Radix Glycyrrhizae triterpenic acid is greater than 50% in the extract.
3, Radix Paeoniae Alba Radix Glycyrrhizae extract according to claim 1, it is characterized in that: extract dry powder and pharmaceutic adjuvant are made oral formulations, injection or transfusion together, and wherein oral formulations is tablet, capsule, granule, pill, powder, lozenge or oral liquid.
4, the preparation method of Radix Paeoniae Alba Radix Glycyrrhizae extract is characterized in that: the Radix Paeoniae Alba or Radix Glycyrrhizae mix or extract respectively, use the 40-80% alcohol reflux, extract three times, merge extractive liquid, is concentrated into when not having alcohol adding distil water to 3 times volume, filtration or centrifugal, filtrate is mixed or is gone up macroporous resin column respectively, is washed with water to no reducing sugar reaction earlier, and reuse 20-95% alcohol is eluted to no glycosides reaction, ethanol elution is evaporated to dried, gets faint yellow or pale brown toner end.
5, preparation method of extract according to claim 4 is characterized in that Radix Paeoniae Alba Radix Glycyrrhizae uses the 60-70% alcohol reflux, and macroporous resin column on the filtrate after washing with water, is washed till no glycosides reaction with 50-70% ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02156681 CN1200723C (en) | 2002-12-19 | 2002-12-19 | White peony and licorice extract and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02156681 CN1200723C (en) | 2002-12-19 | 2002-12-19 | White peony and licorice extract and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1416888A CN1416888A (en) | 2003-05-14 |
| CN1200723C true CN1200723C (en) | 2005-05-11 |
Family
ID=4752799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02156681 Expired - Lifetime CN1200723C (en) | 2002-12-19 | 2002-12-19 | White peony and licorice extract and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1200723C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919913A (en) * | 2010-07-29 | 2010-12-22 | 宁波立华制药有限公司 | Composition with effect of treating rheumatoid arthritis |
| CN102416048A (en) * | 2010-12-06 | 2012-04-18 | 成都中医药大学 | New use of total glucosides of paeony and medicinal composition thereof |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023278A1 (en) * | 2003-09-09 | 2005-03-17 | Molecular Biology Limited | A method of extracting glycyrrhizic flavone and the use of glycyrrhizic flavone for preparing anticarcinogen |
| CN101375954B (en) * | 2007-08-27 | 2011-08-24 | 天津药物研究院 | Medicament composition, preparation method thereof and use |
| CN102416037B (en) * | 2010-12-06 | 2014-02-26 | 成都中医药大学 | Novel application of licorice total saponin as unique active ingredient in preparing medicine for irritable bowel syndrome |
| CN108096120A (en) * | 2018-02-07 | 2018-06-01 | 合肥华盖生物科技有限公司 | A kind of skin-protection type sterilizing hand cleanser and preparation method thereof |
| CN115025113B (en) * | 2022-07-25 | 2023-06-20 | 中国中医科学院中医基础理论研究所 | New use of Paeonia lactiflora and Glycyrrhiza decoction polysaccharide extract |
| CN115040633A (en) * | 2022-07-25 | 2022-09-13 | 中国中医科学院中医基础理论研究所 | New use of protein extract of peony and licorice decoction |
| CN115089694B (en) * | 2022-07-25 | 2023-08-18 | 中国中医科学院中医基础理论研究所 | Glycyrrhiza protein extract and new application thereof |
| WO2024103378A1 (en) * | 2022-11-18 | 2024-05-23 | 谢丞威 | Chinese herbal medicine external formulation for treating muscle soreness and preparation method therefor |
-
2002
- 2002-12-19 CN CN 02156681 patent/CN1200723C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919913A (en) * | 2010-07-29 | 2010-12-22 | 宁波立华制药有限公司 | Composition with effect of treating rheumatoid arthritis |
| CN101919913B (en) * | 2010-07-29 | 2012-12-12 | 宁波立华制药有限公司 | Composition with effect of treating rheumatoid arthritis |
| CN102416048A (en) * | 2010-12-06 | 2012-04-18 | 成都中医药大学 | New use of total glucosides of paeony and medicinal composition thereof |
| CN102416048B (en) * | 2010-12-06 | 2015-01-21 | 成都中医药大学 | New use of total glucosides of paeony and medicinal composition thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1416888A (en) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1319575C (en) | Compound traditional Chinese medicine for treating fracture and injury, prepn. method and use thereof | |
| CN1200723C (en) | White peony and licorice extract and its prepn process | |
| CN1879833A (en) | An wind-expelling ointment and method for preparing same | |
| CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
| CN1947757A (en) | Leave of glutinous rehmannia extractive, its prepn. method and use, medicines prepd. with said extractives | |
| CN101032580A (en) | Medicine for treating rheumatic diseases | |
| CN1583086A (en) | Chinese medicine for relieving exterior syndrome, regulating stomach and eliminatnig dampness and its production | |
| CN1239193C (en) | Chinese medicine for treating trigeminal neuralgia and its preparation method | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1628662A (en) | Medicine with abirritation | |
| CN1220519C (en) | Chinese medicinal composition for treating prostate cancer, its preparation method and its application in the preparation of medicine for treating prostate cancer | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1651036A (en) | Angelica root mistletoe granules and its preparation method | |
| CN1066959C (en) | Medicine for treating hydrocephalus | |
| CN1225250C (en) | Efficacious parts compositions for prevention and cure of senile dementia and preparation method | |
| CN100337665C (en) | Oral medicine for treating diabetes | |
| CN1569195A (en) | Rhodiola sacra soft capsule and its preparation | |
| CN1336233A (en) | Hepatitis B treating medicine | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1640436A (en) | Chinese medicine composition for treating menstrual period syndrome | |
| CN1903343A (en) | Medicine composition for treating biliary tract calculus, prepn. method and use thereof | |
| CN1785348A (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
| CN1650919A (en) | Prescription of Chinese medicine compound preparation, its preparation method and use | |
| CN1839931A (en) | Medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING YINKERUISI PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: CHINA PHARMACEUTICAL RESEARCH + DEVELOPMENT CENTER CO., LTD. Effective date: 20090417 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090417 Address after: Beijing City, Xicheng District Xinfeng Street 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: Beijing Changping District Shahe Exhibition Road No. 27 China Medical Research and Development Center Co Ltd Patentee before: THE NATIONAL INSTITUTES OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT (NIP) |
|
| ASS | Succession or assignment of patent right |
Owner name: HORUS C+K PHARMACEUTICALS, INC. Free format text: FORMER OWNER: BEIJING INCREASE MEDICINE SCIENCE AND TECHNOLOGY CO., LTD. Effective date: 20100528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 ROOM 3003, BLOCK B, TIANCHENG SCIENCE AND TECHNOLOGY PLAZA, NO.2, XINFENG STREET, DEWAI, XICHENG DISTRICT, BEIJING TO: 300350 NO.1, DAGANG SOUTH ROAD, SHUANGGANG TOWN, JINNAN DISTRICT, TIANJIN CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100528 Address after: 300350, No. 1 South Port Road, double Town, Jinnan District, Tianjin Patentee after: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050511 |
|
| CX01 | Expiry of patent term |